Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines

[Pelican Press 0]

Moderna Stock Soars on Cutting-Edge Personalized ******* Vaccines

• Moderna is developing personalized mRNA ******* vaccines, which have shown positive results against melanoma.
• Moderna’s neoantigen mRNA ******* vaccines train the patient’s immune system to target specific ******* cells for termination.
• Moderna’s mRNA-108 dual flu and COVID-19 vaccine showed positive results in Phase 3 trials, generating a greater immune response than separate flu and COVID-19 vaccines.

Biotechnology firm Moderna (NASDAQ:) made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA (mRNA) technology for the development of innovative treatments. The company continues expanding its treatments for various ********* and illnesses, including cardiovascular ********, *******, and other rare *********. Moderna has been working on personalized ******* vaccines that will enable a ******* patient’s immune system to identify and terminate specific ******* cells.

Moderna operates in the medical sector and competes with other biotechnology companies such as Biogen (NASDAQ:), Pfizer (NYSE:), and Amgen (NASDAQ:).

Simple Explanation of How an mRNA Vaccine Works

Vaccines are medical treatments that enable a person’s immune system to ****** ********. mRNA vaccines deliver instructions for the body to produce a harmless version of a virus (spike protein on the surface of SARS-CoV-2) to train the immune system to identify it and create antibodies against it for future encounters. This is an overly simplified explanation of how Moderna’s Spikevax COVID-19 vaccine works. The same mRNA technology methods are being applied to developing a ******* vaccine.

Personalized ******* Treatment Using mRNA Technology

******* vaccine development has been underway for decades. The trend toward mRNA ******* vaccine continues to gain momentum. While mRNA is known for COVID-19 vaccines, they were originally intended to ****** *******. Rather than protecting the body from *******, ******* vaccines train the immune system to target specific ******* cells. mRNA ******* vaccines are personalized, and creating a custom vaccine takes up to 14 weeks. Moderna’s mRNA-4157 neoantigen vaccine for melanoma was used with Merck & Company (NYSE:) Keytruda in a study that showed a 44% reduction of recurrence or ****** for melanoma patients.

Moderna’s Personalized mRNA ******* Vaccine

Moderna’s mRNA ******* vaccines are custom-made by sequencing the DNA of each ******* patient’s tumor and matching them up with 34 neoantigens to create a personalized treatment. The goal is to train the immune system to identify and target the destruction of those ******* cells specifically. Moderna is working on a melanoma treatment and is finishing construction of a facility in Marlborough, Massachusetts, for ******* treatments if approved. Its needle-to-needle time from biopsy to creation and injection of a personal mRNA ******* vaccine averages 75 days, which Moderna is trying to reduce to under 60 days. Moderna is also researching its application for head and neck cancers.

MRNA Stock is Forming a Descending Triangle Breakdown

The daily candlestick chart on MRNA illustrates a potential descending triangle breakdown pattern. The descending upper trendline resistance formed at the $170.47 peak as it capped bounces at sequentially lower highs. The flat-bottom lower trendline formed at $138.17. MRNA has been trending lower for 7 sessions as it tests the lower trendline support. The daily relative strength index (RSI) has also fallen from a peak at the lofty 87-band to the 45-band. Pullback support levels are at $131.72, $121.68, $116.73, and $107.00.

FDA Application Filed for JN.1 Targeting COVID-19 Vaccine

On June 7, 2024, Moderna filed an FDA application for the monovalent JN.1 composition COVID-19 vaccine for the 2024-2025 flu season. The company noted the most commonly solicited systemic adverse events include fatigue, headache, myalgia, and chills.

Moderna Reports Positive Phase 3 Trial Data for Combination Flu and COVID-19 Vaccine

On June 10, 2024, Moderna reported that its combination of influenza and COVID-19 treatment mRNA-1083 met its primary endpoints, triggering a higher immune response than the licensed comparator vaccines used in the trial. The trial consisted of around 4,000 adults split into 2 groups. One group, consisting of adults 65 and older, compared mRNA-1083 to co-administered Fluzone HD (flu vaccine) and Spikevax (COVID-19 vaccine).

The second group consisted of adults 50 to 64 years old and compared mRNA-1083 to co-administered Fluarix (stand flu vaccine) and Spikevax. Both cohorts exhibited a higher immune response for the mRNA-1083 vaccine for 3 strains of influenza (H1n1, H3N2, and B/Victoria) and the Omicron variant of SARS-CoV-2 virus over the combination flu and COVID-19 vaccines.

The Phase 3 clinical trial data for mRNA-1083 will be presented at an upcoming medical conference and submitted for publication as Moderna engages with regulators to discuss the next steps.

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up

#Moderna #Stock #Soars #CuttingEdge #Personalized #******* #Vaccines

This is the hidden content, please

• Sign In
• or
• Sign Up

For verified travel tips and real support, visit: https://hopzone.eu/